Abstract:Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disorder. HCMis characterized by cardiac hypertrophy, fibrosis, and an increased risk of fatalarrhythmias and sudden cardiac death. Previous studies in humans with HCM havedemonstrated increased cardiac norepinephrine spillover and reduced beta-1 receptor(B1R) expression in the left ventricle (LV). We have previously demonstrated thatcardiac sympathetic tone is elevated in an alpha-tropomyosin mutant mouse model ofHCM. We hypothesized that HCM mice would demonstrate reduced B1R expression inthe LV and attenuated heart rate (HR) and dP/dt max responses to ramped infusion of theB1R agonist, dobutamine. First, we utilized western blot to measure B1R proteinexpression in LV tissue from HCM and littermate wild-type (WT) mice (n=4 male micein each group). B1R expression was significantly reduced in the LV of HCM micecompared to WT littermate controls (HCM 60±1% vs. WT 100±4%; paired t-test, p<0.05). Next, we recorded left ventricular pressure in male and female HCM andlittermate WT control (n=5 male mice, each group; n=6 female mice, each group) miceanesthetized with isoflurane (2% in O 2 ). Data were analyzed by 2-way ANOVA withgenotype and sex as factors. Baseline HR and dP/dt max were significantly lower inHCM compared to WT mice (genotype p 0.05). Next, in order to assess cardiac B1R function, we firstinfused the ganglionic blocker chlorisondamine (6ug/g) to eliminate autonomic reflexfunction in HCM and littermate WT mice (n=4 mice, each group). Then, we performed adobutamine stress test via ramped infusion of dobutamine starting at 2ng/g/min andincreasing the dose in 2ng/g/min increments every 2 minutes up to 12ng/g/min via aprogrammable syringe pump. Data were analyzed by 2-way ANOVA with dose andgenotype as factors. Contrary to our hypothesis, ramped infusion of dobutamine resultedin a similar, significant (dose p 0.05). Peak increases in HR occurred during the highest dose ofdobutamine (12ng/g/min; ΔHR HCM 58±19 vs. WT 70±20 beats/min) in both groups.Consistent with our hypothesis, increases in dP/dt max were significantly blunted inHCM mice compared to littermate WT controls (dose x genotype p<0.05). Peakincreases in dP/dt max occurred at a lower dose of dobutamine for HCM (4ng/g/min;ΔdP/dt max 1129±767 mmHg/s) compared to WT (8ng/g/min; ΔdP/dt max 4882±499mmHg/s). In summary, LV B1R expression is reduced in HCM mice. Increases in HR inresponse to ramped infusion of dobutamine were similar between HCM and WT micewhereas increases in dP/dt max were attenuated in HCM mice. We speculate that thedifferential inotropic and chronotropic responses to dobutamine could be due to regionaldifferences in B1R expression or contractile dysfunction in HCM mice. Michigan Technological University Startup. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Abstract 13999: Atrial-Specific BetaM Protein is a Novel Transcriptional Regulator of Cardiac Hypertrophic Response and Myogenesis

Transcriptional Profiling of Rat Skeletal Muscle Hypertrophy under Restriction of Blood Flow.

The transcription factor EBF1 non-cell-autonomously regulates cardiac growth and differentiation

Protein Kinase A Is a Master Regulator of Physiological and Pathological Cardiac Hypertrophy

Identification and characterization of a cardiac-specific transcriptional regulatory element in the slow/cardiac troponin C gene

Abstract 92: the Protective Effect of Β3-Adrenergic Signaling Occurs Via Differential Phosphorylation of Nnos in Cardiac Myocytes

Abstract 19478: the Protective Effect of Beta3-Adrenergic Signaling Occurs Via Differential Phosphorylation of Nnos in Cardiac Myocytes

Sbk2, a Newly Discovered Atrium-Enriched Regulator of Sarcomere Integrity

lncExACT1 and DCHS2 Regulate Physiological and Pathological Cardiac Growth

Reduced Cardiac Beta 1 Receptor Expression and Function in a Mouse Model of Hypertrophic Cardiomyopathy

Myocardin-Related Transcription Factor-A Induces Cardiomyocyte Hypertrophy

Bone morphogenetic protein-2 acts upstream of myocyte-specific enhancer factor 2a to control embryonic cardiac contractility.

Myocardial Brain-Derived Neurotrophic Factor Regulates Cardiac Bioenergetics Through the Transcription Factor Yin Yang 1

Abstract 408: Spliced X-box Binding Protein 1 Promotes Cardiac Hypertrophy Through Activation of Mtorc1

Type III Transforming Growth Factor-β Receptor Drives Cardiac Hypertrophy Through Β-Arrestin2–dependent Activation of Calmodulin-Dependent Protein Kinase II

MicroRNA-133a Protects Against Myocardial Fibrosis and Modulates Electrical Repolarization Without Affecting Hypertrophy in Pressure-Overloaded Adult Hearts.

Abstract 12717: Enhance Negative Modulation of Beta 3 -Adrenergic Stimulation on Cardiomyocyte Functional Performance, [Ca 2+ ] i Regulation and β-Adrenergic Reserve in Rats Expressing Human Angiotensinogen Gene

Intracellular β1-Adrenergic Receptors and Organic Cation Transporter 3 Mediate Phospholamban Phosphorylation to Enhance Cardiac Contractility

Abstract 17320: Signaling Mechanisms Involved in Beta3-adrenergic Receptor Regulation of Nnos in Isolated Cardiomyocytes

Mutual Potentiation Between Myofibril Assembly and Serum Response Factor in Cardiomyocyte Maturation

Abstract 269: RBM20 Knockout Ameliorates Angiotensin II Induced Hypertension and Cardiac Hypertrophy